Central Nervous System Clinical Trial
— B-NETOfficial title:
Brain Networks and Mobility Function: B-NET
Verified date | August 2023 |
Source | Wake Forest University Health Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Rapidly accumulating evidence indicates that the central nervous system (CNS) plays a pivotal role in mobility function with age-associated CNS changes strongly contributing to declining mobility. Studies linking the brain to mobility have used anatomical measures like brain volume and white matter integrity, and suggest that damage to the connecting fibers of the brain (white matter) is related to mobility impairment. Unfortunately, age-related structural white matter damage appears irreversible and only indirectly indicates the functional connectivity between brain regions. It is believed that functional brain network analyses have the potential to identify individuals that may benefit from interventions prior to the development of irreversible white matter lesions. The current project will assess both physical and cognitive function and integrate these variables with measures of brain network connectivity.
Status | Completed |
Enrollment | 192 |
Est. completion date | July 12, 2023 |
Est. primary completion date | July 12, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 70 Years and older |
Eligibility | Inclusion Criteria: - Community-dwelling adults aged =70 years - Willing to provide informed consent; ability to communicate with study personnel. Exclusion Criteria: - Serious or uncontrolled chronic disease such as: - Cancer (stage 3 or 4) or having had radiation or chemotherapy in the past year - Uncontrolled angina - Heart failure (stage 3-4) - Respiratory disease requiring the use of oxygen - Uncontrolled endocrine/metabolic disease (fasting glucose >250mg/dL) - Liver failure (AST > 40IU/L and/or ALT > 44 IU/L) - Renal failure requiring dialysis - Clinically diagnosed neurologic diseases: Parkinson's disease; Amyotrophic Lateral Sclerosis (ALS); Multiple Sclerosis, prior stroke with residual effects lasting longer than 24hrs - Diagnosis of schizophrenia, bipolar, or other psychotic disorder - Diagnosis of Alzheimer's disease or evidence of impaired cognitive function - Prior traumatic brain injury with residual deficits - Unwilling or unable to have an MRI brain scan (see MRI screening form). - Dependent on a walker or another person to ambulate. - Plans to relocate in the next 2- 3 years. - Single or double amputee - Musculoskeletal impairments severe enough to preclude functional testing - Participating in an exercise or cognitive enhancing intervention - Any other reason the PI or study physician feels the participant would not adhere to the protocol |
Country | Name | City | State |
---|---|---|---|
United States | Wake Forest Baptist Medical Center | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Wake Forest University Health Sciences | National Institute on Aging (NIA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Gait Speed | This will be assessed over 4 meters 3 times at usual pace and 3 times at fast pace using an instrumented mat (GAITRite System), which provides data on average step and stride length, initial and terminal double support time, as well as the variability in these measures | baseline and 18 and 30 months | |
Other | Change in lower extremity muscle strength | Maximal isokinetic knee extension and flexion strength will be measured using an isokinetic dynamometer | baseline and 18 and 30 months | |
Other | Change in postural sway | Postural sway during quiet stance will be assessed from Center-of-Pressure (COP) trajectory data collected at 100 Hz using an Advanced Mechanical Technology Incorporated (AMTI) AccuSway biomechanics force platform. | baseline and 18 and 30 months | |
Primary | Change in Extended Short Physical Performance Battery (eSPPB) | The expanded Short Physical Performance Battery (eSPPB) is a modified version of a widely used assessment of lower extremity physical function that consists of 3 standing balance tasks held for 10 seconds each (side-by-side, tandem and semi-tandem), two 4-m walk tests to assess usual gait speed, and 5 repeated chair stands. To minimize ceiling effects and maximize overall dispersion of test scores, the eSPPB increases the holding time of the semi- and full-tandem stands to 30 seconds and adds a single leg stand and a narrow walk test of balance (walking at usual pace within lines of tape spaced 20 cm apart). eSPPB scores are continuous and range from 0 to 4, with higher scores indicative of better performance. | baseline and 6, 18, and 30 months | |
Secondary | Change in Cardiovascular fitness | The fast-paced 400M walk protocol will be used. | baseline and 18 and 30 months | |
Secondary | Change in Digit Symbol Substitution Test (DSST) | The WAIS-III Digit Symbol Substitution Test will be used. | baseline and 18 and 30 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04014491 -
The Effects of Exercise Training on Corticospinal System in Overhead Athletes With Shoulder Impingement Syndrome
|
N/A | |
Terminated |
NCT01006109 -
Recording and Modulation of Neuronal Mechanisms During Operant Conditioning: a MEG Study
|
||
Recruiting |
NCT02559752 -
Computer-based Neurocognitive Assessment in Children With Central Nervous System Tumors Receiving Proton Beam Radiation Therapy
|
||
Terminated |
NCT04644315 -
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
|
Phase 2 | |
Completed |
NCT01531920 -
A Study in Healthy Subjects to Determine the Effects When Alcohol is Administered With Perampanel
|
Phase 1 | |
Completed |
NCT02652260 -
Effects of Switching From ATRIPLAâ„¢ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)
|
Phase 2 | |
Recruiting |
NCT01541800 -
Circulating microRNAs as Disease Markers in Pediatric Cancers
|
N/A | |
Completed |
NCT02343718 -
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
|
Phase 1 | |
Completed |
NCT03830762 -
Xanamemâ„¢ in Healthy Elderly Subjects
|
Phase 1 | |
Completed |
NCT01527006 -
Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs
|
Phase 2 | |
Completed |
NCT01517087 -
Studying Motor Neuron Tests
|
||
Recruiting |
NCT05627986 -
Sensorimotor Cortex Excitability in Shoulder Impingement Syndrome
|
||
Completed |
NCT01432288 -
Touch and Attention MRI Study
|
N/A | |
Completed |
NCT00067067 -
Investigating Endothelial Precursor Cells (EPCs)
|
N/A | |
Completed |
NCT03268239 -
Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions
|
N/A | |
Recruiting |
NCT04846764 -
Rapid Declarative Neocortical Declarative Learning in Aging and Memory Diseases (ANéRAVIMM)
|
N/A |